Patterson Cos에 대한 매도 수량은 투자자에게 Patterson Cos의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Patterson Cos (NASDAQ:PDCO) 주식, 공매도 수량 보고

Patterson Cos

Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.

Patterson Companies

Mid Cap

News

Movers

Trading Ideas

NAMS

NVCR

PDCO

PTVE

STVN

이 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 패터슨(NASDAQ:PDCO)의 주식은 회사가 페이션트 스퀘어 캐피털(Patient Square Capital)에 의해 약 41억 달러에 인수되기로 최종 합의했다고 발표한 후 35.60% 급등했다.

월그린스, 알래스카 에어 및 RH 지난주 최고 성과를 보여준 10개 중형주 중 일부 (12월 9일-13일)

Markets

AMPS

BLCO

BTBT

FYBR

LBPH

LSPD

MSGM

NVAX

SNDR

TCEHY

UBSFF

USAP

새로이 등장한 블록 치과용품 제조업체인 패터슨 컴퍼니즈(NASDAQ:PDCO)가 주주 가치를 높이기 위해 매각 또는 합병을 포함한 전략적 옵션을 모색 중이라고 목요일 발표했다. 이 회사는 거래 과정을 2분기 재무 보고서의 일환으로 공개했다.

딜 디스패치: 유비소프트는 매각 협상 중, 패터슨은 매각 탐색 중, 프로마의 레카로 인수 등

Patterson Companies Inc

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) stock rocketed 35.60% after the company announced it entered into a definitive agreement to be acquired by <a href="https://www.benzinga.com//node/42470172" target="_blank" rel="noreferrer noopener">Patient Square Capital</a><a href="https://www.benzinga.com//node/42470172" target="_blank" rel="noreferrer noopener"> for approximately $4.1 billion</a>.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) shares jumped 34.55% after the company announced topline data from its <a href="https://www.benzinga.com//node/42418025" target="_blank" rel="noreferrer noopener">Phase 3 BROADWAY trial of Obicetrapib</a>.</li>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 21.38% last week following a report from <a href="https://www.benzinga.com//node/42489438" target="_blank" rel="noreferrer noopener">Sky News</a> indicating that Sycamore Partners has approached various potential lenders to fund a possible acquisition of <a href="https://www.benzinga.com//node/42421855" target="_blank" rel="noreferrer noopener">the company</a>.</li>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock rose 19.49%. Piper Sandler maintained an Overweight rating and <a href="https://www.benzinga.com/quote/nvcr/analyst-ratings" target="_blank" rel="noreferrer noopener">raised the price target to $42</a>.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares surged 18.60% after the company reported quarterly<a href="https://www.benzinga.com//node/42474077" target="_blank" rel="noreferrer noopener"> results and raised its guidance</a>. Also, Baird maintained a Neutral rating on the stock and raised its price <a href="https://www.benzinga.com/quote/rh/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $300 to $400</a>.</li>
<li>Pactiv Evergreen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTVE#NASDAQ">PTVE</a>) stock upped 17.71% after the company announced it would merge with Novolex, in which Pactiv <a href="https://www.benzinga.com//node/42387693" target="_blank" rel="noreferrer noopener">shareholders would receive $18.00 per share in cash</a>.</li>
<li>Comstock Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRK#NYSE">CRK</a>) shares escalated 15.70%.</li>
<li>ReNew Energy Global plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) stock rose 15.47% after the company announced it received a $7.07 share buyout proposal from a consortium including Masdar, CPP Investments, ADIA and founder Sumant Sinha <a href="https://www.benzinga.com//node/42438763" target="_blank" rel="noreferrer noopener">to acquire the remaining share capital</a>.</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) stock was up 15.15% after the company unveiled &#8220;Alaska Accelerate,&#8221; a strategy to boost profitability and <a href="https://www.benzinga.com//node/42420282" target="_blank" rel="noreferrer noopener">issued a strong FY25 outlook</a>. Analysts boosted the <a href="https://www.benzinga.com//node/42469812" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Stevanato Group S.p.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) stock upped 13.82%. Wolfe Research initiates coverage with an Outperform rating and a<a href="https://www.benzinga.com/quote/stvn/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast of $28</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42499355/tesla-alphabet-and-broadcom-are-among-top-large-cap-gainers-last-week-december-9-13-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Tesla, Alphabet And Broadcom Are Among Top Large Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42499466/super-micro-computer-adobe-and-nucor-are-among-top-large-cap-losers-last-week-december-9-13-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Shutterstock

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?

On Wednesday,&nbsp;Patient Square Capital, a healthcare investment firm, agreed to acquire&nbsp;Patterson Companies, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>), a dental and animal health product distributor, for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42433177/patterson-companies-announces-definitive-agreement-to-be-acquired-by-patient-square-capital-for-31" rel="noreferrer noopener">approximately $4.1 billion</a>.
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger,&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment" rel="noreferrer noopener">to boost shareholder value</a>.
William Blair notes that based on Patient Square Capital&#8217;s portfolio, which doesn&#8217;t include dental or animal health companies, regulatory hurdles for this deal are unlikely.
Additionally, the analyst&#8217;s dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.
The valuation analysis includes Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), Dentsply Sirona Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), Henry Schein Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), Envista Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) and Europe-listed Straumann Holding.
William Blair writes that most dental companies they cover are trading at or near their lowest valuations in 15 years, as investor interest has declined due to ongoing macroeconomic challenges.
Most recently,&nbsp;Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary&nbsp;suspension of sales, marketing, and shipments of Byte Aligners <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814727/dentsply-sirona-stock-sinks-on-dismal-2024-guidance-blames-macroeconomic-competitiv" rel="noreferrer noopener">and Impression Kits</a>.
Henry Schein&#8217;s third-quarter global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752173/henry-schein-q3-earnings-sees-recovery-from-cyber-incident-says-dental-equipment-business-shows-sta" rel="noreferrer noopener">to $1.1 billion</a>.
While it&#8217;s still early to gauge investor reactions, the analyst is considering whether Patterson&#8217;s acquisition might stabilize valuations and boost demand in the dental sector.
The analyst writes the move could support valuations and signal a potential recovery in the market, making many dental stocks appealing from a risk/reward perspective.
Among these, William Blair sees Align as having the greatest potential for stock growth, driven by improving market conditions and gains in both earnings and valuation.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465586/gevo-and-lg-chem-push-ahead-on-eto-commercialization-for-sustainable-aviation-and-bio-propylene-markets" target="_blank" rel="noreferrer noopener">Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Large Cap

Health Care

Analyst Ratings

General

ALGN

HSIC

NVST

XRAY

What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?

Baird analyst Jeff Johnson maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Neutral and raises the price target from $25 to $31.

Price Target

Baird Maintains Neutral on Patterson Cos, Raises Price Target to $31

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 172.2% to $12.55 during Wednesday's pre-market session. The company's market cap stands at $407.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock rose 34.75% to $0.53. The company's market cap stands at $5.3 million. </li>
<li>Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) stock moved upwards by 34.18% to $31.01. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q2 earnings report came out 4 days ago. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) stock increased by 17.3% to $1.7. The market value of their outstanding shares is at $19.8 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 14.86% to $0.85. The company's market cap stands at $3.6 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares moved upwards by 14.71% to $2.65. The market value of their outstanding shares is at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares declined by 67.0% to $8.05 during Wednesday's pre-market session. The market value of their outstanding shares is at $98.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares decreased by 66.41% to $0.43. The company's market cap stands at $17.7 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares declined by 36.51% to $14.66. The market value of their outstanding shares is at $446.0 million. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares declined by 33.88% to $0.2. </li>
<li>ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock declined by 28.24% to $3.33. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock fell 26.93% to $0.46. The market value of their outstanding shares is at $3.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANAB

BPTH

CADL

CLRB

HEPA

IBRX

MBRX

NIVF

QTTB

SYBX

TFFP

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

U.S. stocks were higher, with the Nasdaq Composite gaining around 300 points on Wednesday.
Shares of Photronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAB#NASDAQ">PLAB</a>) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance with its <a href="https://www.benzinga.com/news/earnings/24/12/42434183/photronics-q4-earnings-beats-expectations-ceo-credits-strong-us-sales-2025-backed-by-ai-edge-computing-and-supply-chain-trends">midpoint above estimates</a>.
The company reported adjusted EPS of 59 cents, beating the Wall Street view of 52 cents. Photronics reported quarterly revenues of $222.63 million, down 2% year-over-year. Sales beat the analyst consensus of $218.00 million. The revenue grew by 6% Q/Q.
Photronics shares jumped 13.1% to $28.64 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) shares jumped 47.8% to $6.80 after the company reported better-than-expected first-quarter EPS and sales and issued strong guidance.</li>
<li>Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) surged 34% to $30.98 after the company announced it entered into a definitive agreement to be acquired by Patient Square Capital.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 18.6% to $2.2892.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) surged 17.3% to $71.95.</li>
<li>FIGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) rose 17.3% to $6.02 following a WSJ report suggesting the company received a takeover offer from Story3 Capital Partners.</li>
<li>ReNew Energy Global Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) jumped 12.1% to $7.11 after the company announced it received $7.07 share buyout proposal from a consortium including Masdar, CPP Investments, ADIA and founder Sumant Sinha to acquire the remaining share capital.</li>
<li>Frontier Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) surged 11.6% to $6.70. Deutsche Bank analyst Michael Linenberg upgraded Frontier Group from Hold to Buy and raised the price target from $6 to $8.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) gained 10.2% to $29.68 following quarterly results.</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) jumped 7.7% to $60.57.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) rose 7.5% to $268.58. Roth MKM analyst Chip Moore initiated coverage on Powell Industries with a Buy rating and announced a price target of $312.</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) gained 5.7% to $346.12 after the company issued FY24 and FY25 revenue guidance.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/24/04/38316287/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call&#8221;&gt;&lt;em&gt; Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call&lt;/em&gt;&lt;/a&gt;

Long Ideas

Intraday Update

DXYZ

FIGS

PLAB

POWL

RBLX

RZLV

SFIX

ULCC

Photronics Posts Upbeat Results, Joins Stitch Fix, Patterson Companies And Other Big Stocks Moving Higher On Wednesday

Leerink Partners analyst Michael Cherny downgrades Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) from Outperform to Market Perform and raises the price target from $29 to $31.35.

Downgrades

Leerink Partners Downgrades Patterson Cos to Market Perform, Raises Price Target to $31.35

On Wednesday, Patient Square Capital, a healthcare investment firm, agreed to acquire Patterson Companies, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>), a dental and animal health product distributor, for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42433177/patterson-companies-announces-definitive-agreement-to-be-acquired-by-patient-square-capital-for-31" rel="noreferrer noopener">approximately $4.1 billion</a>.
Under the terms of the agreement, Patterson shareholders will receive $31.35 in cash per share, representing an approximately 49% premium to Patterson&#8217;s 30 calendar-day volume-weighted average price (VWAP) ending December 4, 2024 (the last trading day before Patterson announcing the evaluation of strategic alternatives).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40601262/patterson-ceo-blames-q1-drag-on-change-healthcare-cyberattack-timing-of-corporate-expenses" rel="noreferrer noopener">Patterson CEO Blames Q1 Drag On Change Healthcare Cyberattack, &#8216;Timing Of Corporate Expenses&#8217;</a>
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger,&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment" rel="noreferrer noopener">to boost shareholder value</a>.
Earnings were mixed, &#8220;given the challenging end market environment,&#8221; said Patterson CEO&nbsp;Don Zurbay.
The company&#8217;s Board of Directors, excluding Zurbay given his position as a Management Director, has unanimously approved the transaction.
Consistent with the Patterson Companies&#8217; commitment to strong governance practices, Zurbay has recused himself from participating in any deliberations or approvals related to the transaction.
The transaction will be financed through a combination of committed equity financing.
The transaction is expected to close in the fourth quarter of Patterson&#8217;s fiscal 2025
Upon completion of the transaction, Patterson will become a privately held company, and its common stock will no longer be traded on the NASDAQ.
Patterson will maintain its headquarters in St. Paul, Minnesota.
Price Action: PDCO stock is up 34.8% at $31.15 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42436387/macys-lowers-annual-profit-forecast-amid-accounting-misstep-stock-tumbles" target="_blank" rel="noreferrer noopener">Macy&#8217;s Lowers Annual Profit Forecast Amid Accounting Misstep, Stock Tumbles</a></li>
</ul>

Dental Product Supplier Patterson Companies Goes Private In $4.1 Billion Deal

WIIM

Patterson shares are trading higher after the company announced it entered into a definitive agreement to be acquired by Patient Square Capital.

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Patterson Companies Enters Definitive Deal To Be Acquired By Patient Square Capital For $31.35 Per Share In Cash; Deal Valued At Approximately $4.1B

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

<h2 class="wp-block-heading">New On The Block</h2>
Dental supply maker Patterson Companies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value. The company disclosed the deal process as part of its <a href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment">second-quarter financial report</a>.
<h2 class="wp-block-heading">Updates From The Block</h2>
EasyHotel is close to being sold. A billionaire-backed firm called London &amp; Regional Properties is bidding against a fund managed by Tristan Capital Partners. The auction process is in its final stages, according to <a href="https://www.bloomberg.com/news/articles/2024-11-27/billionaire-brothers-private-equity-chase-deal-for-easyhotel">Bloomberg</a>.
Ubisoft Entertainment SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UBSFF#OTC">UBSFF</a>) is in talks with Tencent Holdings ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) <a href="https://www.benzinga.com/general/gaming/24/12/42372040/ubisoft-stock-jumps-14-after-reports-of-tencent-buyout">over a potential buyout</a>. According to Reuters, the deal would allow Ubisoft&#8217;s founders, the Guillemot family, to retain control if the company goes private. This development follows a <a href="https://www.benzinga.com/general/gaming/24/09/40801168/ubisoft-is-mismanaged-shareholders-are-hostages-investor-demands-video-game-company-go-private-aft">difficult year for Ubisoft</a>, marked by staff layoffs, disappointing sales, and the closure of several studios. Ubisoft&#8217;s stock jumped 14% after news of the buyout discussions emerged, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Lightspeed Commerce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) is reorganizing. A majority of the restructuring charges will be incurred in the third quarter of fiscal 2025. The focus remains on &#8220;reducing the complexity of our business,&#8221; said Lightspeed founder and CEO Dax Dasilva <a href="https://investors.lightspeedhq.com/English/newsroom/news-details/2024/Lightspeed-Commerce-Announces-Strategic-Reorganization-Continues-to-Optimize-for-Profitable-Growth/default.aspx">said</a>. An analyst told <a href="https://www.paymentsdive.com/news/lightspeed-strategic-reorganization-employee-impact/734300/">Payments Dive</a> that the intent is to set Lightspeed up for a sale. JPMorgan and RBC are advising the process, according to <a href="https://www.bloomberg.com/news/articles/2024-11-07/lightspeed-looks-for-efficiencies-as-strategic-review-continues">Bloomberg</a>.
See Also: <a href="https://www.benzinga.com/general/space/24/12/42376708/nasa-mission-to-land-humans-on-moon-delayed-artemis-3-now-slated-for-mid-2027">NASA Mission To Land Humans On Moon Delayed &#8211; Artemis 3 Now Slated For&#8230;</a>
<h2 class="wp-block-heading">Off The Block</h2>
Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) agreed to sell its Bohumil, Czech Republic manufacturing facility to Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a href="https://www.benzinga.com/pressreleases/24/12/n42308359/novavax-announces-sale-of-czech-republic-manufacturing-site-to-novo-nordisk-for-200-million" target="_blank" rel="noreferrer noopener">for $200 million</a>. The deal includes transferring assets, including a 150,000-square-foot factory <a href="https://www.benzinga.com/24/12/42323263/wegovy-maker-novo-nordisk-to-buy-novavaxs-czech-republic-manufacturing-facility-for-200-million">and the existing workforce</a>.
Schneider National, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) disclosed that it has agreed to acquire Cowan Systems, LLC and its affiliates for approximately $390 <a href="https://www.benzinga.com/pressreleases/24/11/b42167845/schneiders-dedicated-momentum-continues-to-build-with-latest-acquisition-of-cowan-systems-llc" target="_blank" rel="noreferrer noopener">million in cash, subject to adjustments</a>. The deal also includes a separate purchase of related real estate <a href="https://www.benzinga.com/news/mid-cap/24/11/42170700/schneider-expands-its-fleet-390-million-cowan-systems-deal-supercharges-dedicated-services">assets for $31 million</a>.
Renewi, a London-listed waste management company, <a href="https://www.macquarie.com/assets/macq/about/company/macquarie-asset-management/project-earth/joint-statement-regarding-a-final-possible-cash-offer-for-renewi-by-macquarie.pdf">agreed</a> to a preliminary takeover offer from Macquarie Asset Management that values it at 700.9 million pounds ($888.8 million). Renewi had been exploring the sale of certain assets (i.e. its <a href="https://www.globenewswire.com/news-release/2024/10/10/2961009/0/en/Completion-of-divestment-of-UK-Municipal-operations.html">UK Municipal division</a>) in order to reduce debt and focus on its core recycling business in the Netherlands, Belgium, France and Portugal.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Eegee's, a beloved drive-through restaurant chain founded in Tucson in 1971, has filed for Chapter 11 bankruptcy and closed five locations—four in Tucson and one in Phoenix. Despite challenges, Eegee's continues to operate over 20 locations in Tucson and Phoenix. Local media <a href="https://www.kold.com/2024/12/06/eegees-closes-five-restaurants-files-bankruptcy/">reported</a> that the company owes significant debts, including over $1.2 million to Sysco and hundreds of thousands more to other vendors, with total liabilities ranging between $10 million and $50 million. CEO Chris Westcott cited various pressures as reasons for the restructuring, but local residents blamed 39 North Capital, Eegee's owner since 2018.
Trucking company Kal Freight filed for bankruptcy protection, saying its financial condition has been hurt by unprofitable efforts to become a vertically integrated business and a now-questionable investment in additional vehicles during the height of the Covid-19 pandemic. The closely held company also faces litigation, including foreclosure actions, according to the <a href="https://www.wsj.com/articles/trucker-kal-freight-files-for-bankruptcy-protection-06194094">Wall Street Journal</a> citing a filing Thursday in the U.S. Bankruptcy Court in Houston.
Proma Group has <a href="https://www.promagroup.com/archive/news/68">acquired</a> Germany&#8217;s Recaro Automotive GmbH, enabling the company to exit bankruptcy and resume operations across Europe starting January 2025. Recaro's aftermarket seats will return to the market in January, with OEM production shifting to Italy where Proma is based. Several employees from Recaro&#8217;s Sales and Technology departments will remain in the Stuttgart area to ensure a smooth transition and customer support. Recaro&#8217;s operations in North America and Japan remain unaffected. Proma Group CEO Luca Pino praised the partnership as a blend of German industrial and Italian manufacturing excellence.
<h2 class="wp-block-heading">Notes From The Block</h2>
Bain &amp; Company did a swell job putting M&amp;A telecom trends into perspective this week. Here&#8217;s what we learned: 
<ul>
<li>Global deal value &#8220;surged&#8221; from about $24 billion in the first three quarters of 2023 to $90 billion in the same period in 2024, the firm noted. The Americas accounted for 63% of the global total.</li>
<li>Financial investors are acquiring tower and fixed assets. This trend underscores confidence in digital infrastructure's business fundamentals despite headwinds.</li>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40727235/verizon-to-acquire-frontier-in-20b-deal-reaffirms-fy24-outlook">The $20.3 billion deal between</a> Frontier Communications Parent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>) and Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) is the year's largest transaction so far.</li>
<li>Scale deals accounted for nearly half of global deal value year to date; infrastructure divestments accounted for 22% of deal value through the first nine months of 2024 (36% of all deal value over the past five years); mobile and fixed divestments made up about 20% during that period. For the full report, <a href="https://www.bain.com/insights/telecom-m-and-a-here-are-the-latest-deal-trends-worldwide-interactive/">click here</a>.</li>
</ul>
For last week&#8217;s <a href="https://www.benzinga.com/news/asset-sales/24/11/42254293/deal-dispatch-stoli-bankrupt-ally-financial-to-sell-credit-card-unit">Deal Dispatch, click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42370712/bitcoins-flash-crash-is-a-classic-bull-market-shakeout-says-trader-watch-these-3-scenarios">Bitcoin Flash Crash: Classic Bull Market Shakeout?</a></li>
</ul>

Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt

During the last three months, 4 analysts shared their evaluations of Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.75, with a high estimate of $25.00 and a low estimate of $22.00. A decline of 6.86% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1733497232_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Patterson Cos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Patterson Cos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Patterson Cos compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Patterson Cos's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PDCO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Patterson Cos analyst ratings.</a>
<h2>Get to Know Patterson Cos Better</h2>
Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.
<h3>A Deep Dive into Patterson Cos's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Patterson Cos's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately -2.22%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Patterson Cos's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Patterson Cos's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Patterson Cos's ROA excels beyond industry benchmarks, reaching 0.48%. This signifies efficient management of assets and strong financial health.
Debt Management: Patterson Cos's debt-to-equity ratio is below the industry average. With a ratio of 0.94, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 4 Analyst Insights On Patterson Cos

Piper Sandler analyst Jason Bednar maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Neutral and lowers the price target from $26 to $24.

Piper Sandler Maintains Neutral on Patterson Cos, Lowers Price Target to $24

Baird analyst Jeff Johnson maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Neutral and lowers the price target from $28 to $25.

Baird Maintains Neutral on Patterson Cos, Lowers Price Target to $25

Stifel analyst Jonathan Block maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Hold and lowers the price target from $25 to $24.

Stifel Maintains Hold on Patterson Cos, Lowers Price Target to $24

Dental supply maker Patterson Companies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) announced Thursday that it is exploring strategic options, including a sale or merger, <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">to boost shareholder value</a>. 
What Happened: The company disclosed the sale process as part of its second-quarter financial report. 
Earnings were mixed, &#8220;given the challenging end market environment,&#8221; said Patterson CEO Don Zurbay.
Patterson posted second-quarter 2025 net sales of $1.67 billion. That&#8217;s up <a href="https://www.benzinga.com/pressreleases/24/12/b42335427/patterson-companies-reports-fiscal-2025-second-quarter-operating-results" target="_blank" rel="noreferrer noopener">1.3% year-over-year</a>. Wall Street expected a <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">net sales of $1.65 billion</a>. Internal sales increased just 0.6%.
Here&#8217;s a breakdown of the dental business:
<ul>
<li>Dental segment sales reached $611.7 million. </li>
<li>Internal sales decreased 2.3%. </li>
<li>Internal sales of equipment decreased 7.5%. </li>
<li>Internal sales of value-added services decreased 2.7% — likely due to a cybersecurity <a href="https://www.benzinga.com/news/earnings/24/08/40601262/patterson-ceo-blames-q1-drag-on-change-healthcare-cyberattack-timing-of-corporate-expenses">attack on Change Healthcare</a>. </li>
</ul>
As for Patterson&#8217;s animal health segment: 
<ul>
<li>Sales reached $1.05 billion. </li>
<li>Internal sales increased 1.9%. </li>
<li>Internal sales of consumables increased 1.6%</li>
<li>Equipment increased 1.4%, and </li>
<li>Value-added services increased 17.1%.</li>
</ul>
The company reported adjusted EPS of 47 cents. That&#8217;s down from 50 cents a year ago. It missed the consensus of 49 cents. 
GAAP and adjusted earnings were also negatively impacted by the Change Healthcare cyber attack.
Patterson &#8220;took dedicated cost management actions&#8221; and &#8220;made targeted investments in complementary businesses,&#8221; according to Zurbay.
Outlook: Patterson expects fiscal year 2025 adjusted EPS Of $2.25-$2.35 compared to the consensus of $2.32 and <a href="https://www.benzinga.com/news/earnings/24/08/40601262/patterson-ceo-blames-q1-drag-on-change-healthcare-cyberattack-timing-of-corporate-expenses" target="_blank" rel="noreferrer noopener">prior guidance of $2.33-$2.43</a>.
Price Action: Patterson stock is up 6.54% at $23.31 during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42339652/kroger-pauses-buybacks-for-albertsons-merger-q3-sales-miss-estimates-fy24-outlook-narrowed" target="_blank" rel="noreferrer noopener">Warren Buffett&#8217;s Portfolio Stock Kroger Pauses Buybacks For Albertsons Merger, Narrows FY24 Outlook</a></li>
</ul>

Earnings

Guidance

Dental Supplier Patterson Companies Is Up For Sale After Posting Mixed Q2 Earnings

Patterson Companies shares are trading higher after the company reported better-than-expected Q2 sales results.

Fiscal 2025 Guidance
Patterson Companies today revised its fiscal 2025 earnings guidance, which is provided on both a GAAP and non-GAAP adjusted1 basis:
<ul>
<li>GAAP earnings are expected to be in the range of $1.83 to $1.93 per diluted share.</li>
<li>Non-GAAP adjusted earnings1 are expected to be in the range of $2.25 to $2.35 per diluted share.</li>
<li>Our non-GAAP adjusted earnings1 guidance excludes the after-tax impact of:&nbsp; - Deal amortization expenses of approximately $29.9 million ($0.34 per diluted share).&nbsp; - Integration and business restructuring expenses of $7.6 million ($0.09 per diluted share).&nbsp; - Inventory pre-payment write-off of $2.8 million ($0.03 per diluted share).&nbsp; - Investment gain of $2.9 million ($0.03 per diluted share).</li>
</ul>
Our guidance reflects the strength of our business and competitive positioning as well as completed and previously announced acquisitions. It does not include the impact of unplanned share repurchases, potential future acquisitions or similar transactions, impairments, restructuring and integration expenses not previously publicly disclosed, or amortization expense of acquired intangible assets. Our guidance assumes North American and international end market conditions consistent with current market conditions.

Patterson Companies Expects 2025 Adjusted EPS Of $2.25-$2.35 Vs. Consensus Of $2.32 And Prior Guidance Of $2.33-$2.43

Patterson Companies Also Announced That It Is Evaluating Potential Strategic Alternatives To Maximize Shareholder Value

Patterson Companies stock is undergoing an extreme rally on Wednesday alongside news that Patient Square Capital will take it private.

M&A News: Patterson Companies Stock (PDCO) Rallies on Patient Square Deal

Mizuho Securities analyst Steven Valiquette has maintained their neutral stance on PDCO stock, giving a Hold rating yesterday. Steven Valiquette's ...

Hold Rating Maintained for Patterson Companies Amid Acquisition by Patient Square Capital

Baird raised the firm's price target on Patterson Companies (PDCO) to $31 from $25 and keeps a Neutral rating on the shares. The firm noted they an...

Patterson Companies price target raised to $31 from $25 at Baird

J.P. Morgan analyst John Stansel maintained a Hold rating on Patterson Companies (PDCO – Research Report) yesterday and set a price target of $25.0...

J.P. Morgan Remains a Hold on Patterson Companies (PDCO)

BofA moves to No Rating on Patterson Companies (PDCO) after the company announced that it has signed a definitive agreement to be acquired by Patie...

BofA moves to No Rating on Patterson Companies after go-private deal

Patterson Companies Surges As The Market Prices In More Upside (Rating Downgrade)

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Adobe (ADBE) reported better-than-expe...

Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz

Patterson Cos. trades near deal price even as analysts see higher bid unlikely

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Broadcom (AVGO) jumped as enthusiasm a...

Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz

Key deals for the week: Patterson, Hershey & Mondelez, AIG & Nippon and more

ADBE

AFRM

AMCR

AMZN

AVGO

BERY

CHTR

CIEN

CMCSA

COST

CRBG

CTLT

EEFT

ELVA

EVGO

HNDAF

HURA

KVUE

LOVE

MDLZ

NDSN

NFLX

NVDA

PENN

RVNC

SCHW

SNPS

SNYNF

SSNLF

TASK

TMUS

TMVWF

TMVWY

TUWLF

UPBD

VWAGY

VWAPY

Press Releases

Patterson Companies Announces Definitive Agreement to Be Acquired by Patient Square Capital for $31.35 Per Share in Cash

Shareholder Alert: Ademi LLP Investigates Whether Patterson Companies, Inc. Is Obtaining a Fair Price for Its Public Shareholders

PDCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Patterson Companies, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NAPA, ML, PDCO on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Patterson Companies, Inc. - PDCO

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, FLIC, MNTX on Behalf of Shareholders

Kuehn Law Encourages AE, STAF, NBR, and PDCO Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CFB, ARCH, PDCO on Behalf of Shareholders

SHAREHOLDER ALERT MNTX, PDCO, FLIC, ML: The M&A Class Action Firm Launches Legal Inquiry

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders

Comments

Patterson Cos

매도 수량

Patterson Cos (NASDAQ:PDCO) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌